Dr. Yabing Zheng 郑亚兵
Chief Physician
Department of Medical Oncology (Breast Cancer), Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast hyperplasia, breast nodules, breast discharge, and breast cancer.
Dr. Zheng holds a Master of Medicine from Zhejiang University School of Medicine and has worked since 1999. With over 16 years in medical oncology, Dr. Zheng focuses on comprehensive and individualized care for solid tumors, including breast, lung, gastric, colorectal, and esophageal cancers, as well as malignant lymphoma. Expertise includes chemotherapy, targeted therapy, endocrine therapy, and palliative care based on molecular subtyping. Dr. Zheng has participated in national research projects, led provincial studies, contributed to over 40 clinical trials, published more than ten papers, and co-edited a book on breast cancer treatment.
Name order: in Chinese the family name comes first (Zheng Yabing). Papers usually list the name as Yabing Zheng or Zheng Y.
Selected publications
38 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Med Sci, 2026 (senior author): Integration of Single-cell and Bulk Transcriptome Analyses Unravels a Macrophage-based Gene Signature for Prognostication and Treatment in Triple-negative Breast Cancer. PubMed 41399382
- Genomics, 2024 (senior author): FOXCUT regulates the malignant phenotype of triple-negative breast Cancer via the miR-337-3p/ANP32E Axis. PubMed 38944356
- Breast Cancer Res Treat, 2024 (senior author): Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis. PubMed 37924380
- Nat Commun, 2023 (first author): Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. PubMed 38097605
- Mol Med Rep, 2016 (first author): Role of estrogen receptor in breast cancer cell gene expression. PubMed 27035558
- Oncol Rep, 2016 (first author): MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. PubMed 26572075
- Cancer Invest, 2016 (first author): Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer. PubMed 26934461
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion